ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody Jun 18, 2008
In addition, ThromboGenics and BioInvent could potentially receive up to EUR450 million over the term of the collaboration based on the successful completion of a series of development and commercial milestones for multiple indications, as well as double digit royalties on potential product sales, including any backup antibodies based on inhibition of PlGF. ThromboGenics, which discovered TB-403, will receive 60% and BioInvent 40% of the revenue from the deal ... Professor Dsir Collen, CEO... (PR Newswire)
Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO Jun 2, 2008
Pharmacodynamic analyses demonstrated statistically significant changes at the MTD in plasma markers including VEGF-A, PlGF, and soluble VEGFR2, similar to the effects of other anti-angiogenic agents, and consistent with the anti-VEGFR activity of XL184. In addition, decreases in soluble MET were measured in 4 of 7 patients at the MTD who were analyzed for this endpoint. (PR Newswire)
Extra Drug Improves Rectal Cancer Treatment Apr 17, 2008
Avastin alone, or in combination with other treatments, increased levels of the factors VEGF, PlGF and SDF1 alpha, the researchers reported. Patients with higher levels of VEGF and PlGF after Avastin responded better to chemotherapy and radiation, Jain said. (MEDLINEplus)
ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer Jan 18, 2008
TB-403 is a monoclonal antibody that targets the angiogenic factor PlGF (placental growth factor). TB-403 has demonstrated strong inhibition of PlGF-associated angiogenesis and tumour growth in animal models, without affecting healthy tissues ... PlGF is a homologue of VEGF but, unlike other angiogenesis factors such as VEGF, it does not affect normal, physiological angiogenesis and is only involved in the angiogenesis process which takes place in the diseased tissue. (PR Newswire)
Antibody might help starve cancerous tumors Nov 5, 2007
The scientists found in studies of mice that an antibody against so-called placental growth factor (PlGF) blocks the growth and spread of many types of tumors ... "Since they work in essentially the same way, a combination treatment of these agents hasn't added much benefit in prolonging survival of cancer patients. We need complementary drug targets and we believe PlGF might be one. It needs to stand the test of time and rigorous clinical testing, but the findings in mice look promising." ...... (News-Medical.net)
ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell Nov 2, 2007
LEUVEN, Belgium and LUND, Sweden, November 2 /PRNewswire/ -- - Novel Anti-PlGF Antibody, TB-403, Being Developed by ThromboGenics and BioInvent for Cancer Expected to Enter the Clinic Later This Year ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, and co-development partner, BioInvent International (Nordic Exchange: BINV), announce today the publication of data in Cell(1) that highlight for the first time the therapeutic potential of anti-PlGF... (PR Newswire)
